MBX Biosciences, Inc. (NASDAQ: MBX) reported a net loss of $0.49 per share for its fourth quarter of 2025, beating the consensus estimate of –$0.61 by $0.12, a 19.7% improvement. The company posted a total net loss of $22.1 million for the quarter, compared with $15.6 million in the same period a year earlier.
Operating expenses rose, with research and development costs climbing to $19.8 million from $15.2 million in Q4 2024, while general and administrative expenses also increased. The wider net loss reflects the company’s continued investment in its clinical pipeline, even as it managed to keep the loss per share lower than analysts expected.
Cash, cash equivalents and marketable securities stood at $373.7 million as of December 31 2025, and rose to $459.1 million on a pro‑forma basis after a February 4 2026 ATM program raise. Management projects that the enhanced cash position will support operations through 2029, providing a runway that underpins the company’s long‑term development plans.
The company’s clinical portfolio remains a key focus. In the fourth quarter, MBX announced a successful End‑of‑Phase 2 meeting with the FDA for canvuparatide, a once‑weekly therapy for chronic hypoparathyroidism, and outlined plans to launch a Phase 3 trial in Q3 2026. The obesity candidate MBX 4291, a GLP‑1/GIP co‑agonist prodrug, is in Phase 1 and is expected to deliver 12‑week MAD data in Q4 2026. CEO Kent Hawryluk said, “2025 was a year of continued growth and execution for MBX, highlighted by the clinical validation of our Precision Endocrine Peptide (PEP™) platform.” He added, “Following a successful End‑of‑Phase 2 meeting with the FDA, we now have a clear path to initiate our Phase 3 trial of once‑weekly canvuparatide. We are also advancing a growing obesity pipeline, built on our clinically validated PEPTM platform and designed for once‑monthly dosing and improved tolerability.”
While the company’s loss widened year‑over‑year, the lower loss per share and the steady cash runway suggest disciplined financial management amid aggressive pipeline investment. The positive regulatory milestone for canvuparatide and the upcoming data for MBX 4291 provide tangible progress signals that may influence future revenue prospects once the company transitions from pre‑revenue to first‑time sales.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.